Poxel to Report Half Year Results for 2019 and Host Conference Call on August 26, 2019

LYON, France--(BUSINESS WIRE)-- POXEL SA (Euronext: POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), will report its financial results for the first half of 2019 on August 26, 2019.

The management team will host an investor conference call on August 26, 2019 in English at 2:00 pm EDT (New York Time) / 7:00 pm CEST (Paris Time) to discuss the financial results and provide a corporate update. To participate in the call, please use the dial-in numbers below according to your location.

US: +1 646-722-4916
France: +33 (0)1 72 72 74 03
UK: + 442071943759
Access Code PIN: 63877744#

Following the live call, a replay will be available for 90 days. To access the replay, please use one of the following numbers.

US: +1 646-722-4969
FR: +33 (0)1 70710160
UK: +44 203364 5147
Access Code PIN: 418869005#

About Poxel SA
Poxel uses its development expertise in metabolism to advance a pipeline of drug candidates focused on the treatment of metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH). Our first-in-class lead product, Imeglimin, targets mitochondrial dysfunction. Together, with our partner Sumitomo Dainippon Pharma, we are conducting the Phase 3 Trials of IMeglimin for Efficacy and Safety (TIMES) program for the treatment of type 2 diabetes in Japan. Our partner Roivant Sciences is responsible for Imeglimin’s development and commercialization in countries outside of Poxel’s partnership with Sumitomo Dainippon Pharma, including the U.S. and Europe. PXL770, a first in class direct adenosine monophosphate-activated protein kinase (AMPK) activator, is in a Phase 2a proof-of-concept program for the treatment of NASH. PXL770 could also have the potential to treat additional metabolic diseases. PXL065 (deuterium-stabilized R-pioglitazone), a mitochondrial pyruvate carrier (MPC), is in Phase 1 and being developed for the treatment of NASH. Poxel also has additional earlier-stage programs, including deuterated drug candidates for metabolic, specialty and rare diseases. We intend to generate further growth through strategic partnerships and pipeline development. (Euronext: POXEL, www.poxelpharma.com)

Poxel SA
Jonae R. Barnes
Senior Vice President, Investor Relations and Public Relations
+1 (617) 818-2985

Investor relations / Media - EU/US
Trophic Communications
Stephanie May or Joanne Tudorica
may@trophic.eu or tudorica@trophic.eu
+49 89 238 877 34 or +49 171 185 56 82

Investor relations / Media - France
Alexia Faure/Arthur Rouillé
+33 1 44 71 98 55

Source: POXEL SA